Risk stratification of childhood medulloblastoma in the molecular era: the current consensus

Historical risk stratification criteria for medulloblastoma rely primarily on clinicopathological variables pertaining to age, presence of metastases, extent of resection, histological subtypes and in some instances individual genetic aberrations such as MYC and MYCN amplification. In 2010, an inter...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Ramaswamy, Vijay (VerfasserIn) , Milde, Till (VerfasserIn) , Pfister, Stefan (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 4 April 2016
In: Acta neuropathologica
Year: 2016, Jahrgang: 131, Heft: 6, Pages: 821-831
ISSN:1432-0533
DOI:10.1007/s00401-016-1569-6
Online-Zugang:Verlag, Volltext: https://doi.org/10.1007/s00401-016-1569-6
Volltext
Verfasserangaben:Vijay Ramaswamy, Marc Remke, Eric Bouffet, Simon Bailey, Steven C. Clifford, Francois Doz, Marcel Kool, Christelle Dufour, Gilles Vassal, Till Milde, Olaf Witt, Katja von Hoff, Torsten Pietsch, Paul A. Northcott, Amar Gajjar, Giles W. Robinson, Laetitia Padovani, Nicolas André, Maura Massimino, Barry Pizer, Roger Packer, Stefan Rutkowski, Stefan M. Pfister, Michael D. Taylor, Scott L. Pomeroy

MARC

LEADER 00000caa a2200000 c 4500
001 1675909962
003 DE-627
005 20230427154455.0
007 cr uuu---uuuuu
008 190904s2016 xx |||||o 00| ||eng c
024 7 |a 10.1007/s00401-016-1569-6  |2 doi 
035 |a (DE-627)1675909962 
035 |a (DE-599)KXP1675909962 
035 |a (OCoLC)1341242449 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Ramaswamy, Vijay  |e VerfasserIn  |0 (DE-588)1194111661  |0 (DE-627)1675909687  |4 aut 
245 1 0 |a Risk stratification of childhood medulloblastoma in the molecular era  |b the current consensus  |c Vijay Ramaswamy, Marc Remke, Eric Bouffet, Simon Bailey, Steven C. Clifford, Francois Doz, Marcel Kool, Christelle Dufour, Gilles Vassal, Till Milde, Olaf Witt, Katja von Hoff, Torsten Pietsch, Paul A. Northcott, Amar Gajjar, Giles W. Robinson, Laetitia Padovani, Nicolas André, Maura Massimino, Barry Pizer, Roger Packer, Stefan Rutkowski, Stefan M. Pfister, Michael D. Taylor, Scott L. Pomeroy 
264 1 |c 4 April 2016 
300 |a 11 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 04.09.2019 
520 |a Historical risk stratification criteria for medulloblastoma rely primarily on clinicopathological variables pertaining to age, presence of metastases, extent of resection, histological subtypes and in some instances individual genetic aberrations such as MYC and MYCN amplification. In 2010, an international panel of experts established consensus defining four main subgroups of medulloblastoma (WNT, SHH, Group 3 and Group 4) delineated by transcriptional profiling. This has led to the current generation of biomarker-driven clinical trials assigning WNT tumors to a favorable prognosis group in addition to clinicopathological criteria including MYC and MYCN gene amplifications. However, outcome prediction of non-WNT subgroups is a challenge due to inconsistent survival reports. In 2015, a consensus conference was convened in Heidelberg with the objective to further refine the risk stratification in the context of subgroups and agree on a definition of risk groups of non-infant, childhood medulloblastoma (ages 3-17). Published and unpublished data over the past 5 years were reviewed, and a consensus was reached regarding the level of evidence for currently available biomarkers. The following risk groups were defined based on current survival rates: low risk (>90 % survival), average (standard) risk (75-90 % survival), high risk (50-75 % survival) and very high risk (<50 % survival) disease. The WNT subgroup and non-metastatic Group 4 tumors with whole chromosome 11 loss or whole chromosome 17 gain were recognized as low-risk tumors that may qualify for reduced therapy. High-risk strata were defined as patients with metastatic SHH or Group 4 tumors, or MYCN-amplified SHH medulloblastomas. Very high-risk patients are Group 3 with metastases or SHH with TP53 mutation. In addition, a number of consensus points were reached that should be standardized across future clinical trials. Although we anticipate new data will emerge from currently ongoing and recently completed clinical trials, this consensus can serve as an outline for prioritization of certain molecular subsets of tumors to define and validate risk groups as a basis for future clinical trials. 
650 4 |a Genomics 
650 4 |a Group 3 
650 4 |a Group 4 
650 4 |a Medulloblastoma 
650 4 |a Outcomes 
650 4 |a p53 
650 4 |a SHH 
650 4 |a Subgroups 
650 4 |a WNT 
700 1 |a Milde, Till  |d 1973-  |e VerfasserIn  |0 (DE-588)1038311837  |0 (DE-627)75711234X  |0 (DE-576)39229334X  |4 aut 
700 1 |a Pfister, Stefan  |d 1974-  |e VerfasserIn  |0 (DE-588)123850215  |0 (DE-627)706450930  |0 (DE-576)293908400  |4 aut 
773 0 8 |i Enthalten in  |t Acta neuropathologica  |d Berlin : Springer, 1961  |g 131(2016), 6, Seite 821-831  |h Online-Ressource  |w (DE-627)253389666  |w (DE-600)1458410-4  |w (DE-576)072283092  |x 1432-0533  |7 nnas  |a Risk stratification of childhood medulloblastoma in the molecular era the current consensus 
773 1 8 |g volume:131  |g year:2016  |g number:6  |g pages:821-831  |g extent:11  |a Risk stratification of childhood medulloblastoma in the molecular era the current consensus 
856 4 0 |u https://doi.org/10.1007/s00401-016-1569-6  |x Verlag  |x Resolving-System  |3 Volltext 
951 |a AR 
992 |a 20190904 
993 |a Article 
994 |a 2016 
998 |g 123850215  |a Pfister, Stefan  |m 123850215:Pfister, Stefan  |d 910000  |d 910500  |e 910000PP123850215  |e 910500PP123850215  |k 0/910000/  |k 1/910000/910500/  |p 23 
998 |g 1038311837  |a Milde, Till  |m 1038311837:Milde, Till  |d 910000  |d 910500  |e 910000PM1038311837  |e 910500PM1038311837  |k 0/910000/  |k 1/910000/910500/  |p 10 
999 |a KXP-PPN1675909962  |e 3511651921 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"disp":"Risk stratification of childhood medulloblastoma in the molecular era the current consensusActa neuropathologica","pubHistory":["1.1961/62 -"],"origin":[{"dateIssuedKey":"1961","publisherPlace":"Berlin ; Heidelberg","dateIssuedDisp":"1961-","publisher":"Springer"}],"recId":"253389666","physDesc":[{"extent":"Online-Ressource"}],"language":["eng","ger"],"id":{"issn":["1432-0533"],"zdb":["1458410-4"],"eki":["253389666"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title":"Acta neuropathologica","title_sort":"Acta neuropathologica"}],"note":["Gesehen am 02.12.2005"],"part":{"pages":"821-831","volume":"131","text":"131(2016), 6, Seite 821-831","issue":"6","extent":"11","year":"2016"}}],"name":{"displayForm":["Vijay Ramaswamy, Marc Remke, Eric Bouffet, Simon Bailey, Steven C. Clifford, Francois Doz, Marcel Kool, Christelle Dufour, Gilles Vassal, Till Milde, Olaf Witt, Katja von Hoff, Torsten Pietsch, Paul A. Northcott, Amar Gajjar, Giles W. Robinson, Laetitia Padovani, Nicolas André, Maura Massimino, Barry Pizer, Roger Packer, Stefan Rutkowski, Stefan M. Pfister, Michael D. Taylor, Scott L. Pomeroy"]},"origin":[{"dateIssuedDisp":"4 April 2016","dateIssuedKey":"2016"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"Risk stratification of childhood medulloblastoma in the molecular era","subtitle":"the current consensus","title_sort":"Risk stratification of childhood medulloblastoma in the molecular era"}],"person":[{"roleDisplay":"VerfasserIn","family":"Ramaswamy","display":"Ramaswamy, Vijay","role":"aut","given":"Vijay"},{"roleDisplay":"VerfasserIn","display":"Milde, Till","family":"Milde","role":"aut","given":"Till"},{"role":"aut","given":"Stefan","display":"Pfister, Stefan","family":"Pfister","roleDisplay":"VerfasserIn"}],"note":["Gesehen am 04.09.2019"],"recId":"1675909962","physDesc":[{"extent":"11 S."}],"language":["eng"],"id":{"doi":["10.1007/s00401-016-1569-6"],"eki":["1675909962"]}} 
SRT |a RAMASWAMYVRISKSTRATI4201